

Reference List



The Ultimate Quiz Show on the Pathophysiology of Rheumatoid and Psoriatic Arthritis

Question 1

Alunno A, Carubbi F, Giacomelli R, Gerli R. Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets. *BMC Rheumatol.* 2017;1:3.

Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. *Nat Rev Rheumatol.* 2019;15(1):9-17.

Lubberts E, van den Berg WB. Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013.

Mateen S, Moin S, Khan AQ, Zafar A, Fatima N. Increased reactive oxygen species formation and oxidative stress in rheumatoid arthritis. *PLoS One.* 2016;11(4):e0152925.

Question 2

Ahmad HA, Alemao E, Guo Z, et al. Association of low bone mineral density with anti-citrullinated protein antibody positivity and disease activity in established rheumatoid arthritis: findings from a US observational cohort. *Adv Ther.* 2018;35(2):232-242.

Bugatti S, Bogliolo L, Vitolo B, Manzo A, Montecucco C, Caporali R. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. *Arthritis Res Ther.* 2016;18(1):226.

Catrina AI, Svensson CI, Malmström V, Schett G, Klareskog L. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. *Nat Rev Rheumatol.* 2017;13(2):79-86.

de Brito Rocha S, Baldo DC, Andrade LEC. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. *Adv Rheumatol.* 2019;59(1):2.

Sun M, Rethi B, Krishnamurthy A, et al. Anticitrullinated protein antibodies facilitate migration of synovial tissue-derived fibroblasts. *Ann Rheum Dis.* 2019;78(12):1621-1631.

Question 3

de Brito Rocha S, Baldo DC, Andrade LEC. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. *Adv Rheumatol.* 2019;59(1):2.

Laurent L, Anquetil F, Clavel C, et al. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. *Ann Rheum Dis.* 2015;74(7):1425-1431.

Question 4

Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. *Semin Immunopathol.* 2017;39(4):437-446.

Handunnetthi L, Ramagopalan SV, Ebers GC, Knight JC. Regulation of major histocompatibility complex class II gene expression, genetic variation and disease. *Genes Immun.* 2010;11(2):99-112.

Kerlan-Candon S, Combe B, Vincent R, Clot J, Pinet V, Eliaou JF. *HLA-DRB1* gene transcripts in rheumatoid arthritis. *Clin Exp Immunol.* 2001;124(1):142-149.

Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of *HLA-DRB1* genes on disease severity in rheumatoid arthritis. *Ann Intern Med.* 1992;117(10):801-806.



The Ultimate Quiz Show on the Pathophysiology of Rheumatoid and Psoriatic Arthritis

Question 5

Ajeganova S, Huizinga TW. Seronegative and seropositive RA: alike but different? *Nat Rev Rheumatol*. 2015;11(1):8-9.

Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis*. 2006;65(7):845-851.

Boeters DM, Burgers LE, Sasso EH, Huizinga TWJ, van der Helm-van Mil AHM. ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. *Arthritis Res Ther*. 2019;21(1):121.

Daha NA, Toes RE. Rheumatoid arthritis: Are ACPA-positive and ACPA-negative RA the same disease? *Nat Rev Rheumatol*. 2011;7(4):202-203.

Heidari B, Firouzjahi A, Heidari P, Hajian K. The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis. *Ann Saudi Med*. 2009;29(6):467-470.

Ohmura K, Terao C, Maruya E, et al. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. *Rheumatology*. 2010;49(12):2298-2304.

Seegobin SD, Ma MH, Dahanayake C, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. *Arthritis Res Ther*. 2014;16(1):R13.

Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. *Arthritis Rheum*. 2011;63(4):933-938.

Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. *Ann Rheum Dis*. 2008;67(2):212-217.

van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum*. 2007;56(5):1424-1432.

Question 6

Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. *PLoS Genet*. 2008;4(3):e1000041.

O'Rielly DD, Jani M, Rahman P, Elder JT. The genetics of psoriasis and psoriatic arthritis. *J Rheumatol Suppl*. 2019;95:46-50.

Rahmati S, Tsoi L, O'Rielly D, Chandran V, Rahman P. Complexities in genetics of psoriatic arthritis. *Curr Rheumatol Rep*. 2020;22(4):10.

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. *N Engl J Med*. 2017;376(10):957-970.

Question 7

Cantatore FP, Maruotti N, Corrado A, Ribatti D. Angiogenesis dysregulation in psoriatic arthritis: molecular mechanisms. *Biomed Res Int*. 2017;2017:5312813.

Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. *J Rheumatol*. 2003;30(2):260-268.

Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D. An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets. *Wien Klin Wochenschr*. 2016;128(21-22):791-795.



The Ultimate Quiz Show on the Pathophysiology of Rheumatoid and Psoriatic Arthritis

Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. *Ann Rheum Dis.* 2002;61(4):298-304.

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. *N Engl J Med.* 2017;376(10):957-970.

Veale DJ, Fearon U. What makes psoriatic and rheumatoid arthritis so different? *RMD Open.* 2015;1(1):e000025.

Question 8

Busse K, Liao W. Which psoriasis patients develop psoriatic arthritis? *Psoriasis Forum.* 2010;16(4):17-25.

Tey HL, Ee HL, Tan AS, Theng TS, Wong SN, Khoo SW. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. *J Dermatol.* 2010;37(5):426-430.

Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. *Arthritis Rheum.* 2009;61(2):233-239.

Question 9

Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. *Int J Mol Sci.* 2018;19(2):530.

Li J, Liu L, Rui W, et al. New interleukins in psoriasis and psoriatic arthritis patients: the possible roles of interleukin-33 to interleukin-38 in disease activities and bone erosions. *Dermatology.* 2017;233(1):37-46.

McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet.* 2013;382(9894):780-789.

Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. *J Rheumatol.* 1998;25(8):1544-1552.

Question 10

Colucci S, Brunetti G, Cantatore FP, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. *J Pathol.* 2007;212(1):47-55.

Gao W, McGarry T, Orr C, McCormick J, Veale DJ, Fearon U. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. *Ann Rheum Dis.* 2016;75(1):311-315.

Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. *N Engl J Med.* 2017;377(16):1525-1536.

Nash P, Coates LC, Fleischmann R, et al. Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. *Rheumatol Ther.* 2018;5(2):567-582.

Yokota K, Sato K, Miyazaki T, et al. Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. *Arthritis Rheumatol.* 2014;66(1):121-129.